DiaMedica Therapeutics Inc. Common Stock

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DMAC and other ETFs, options, and stocks.

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).

CEO

Rick John Pauls

CEORick John Pauls

Employees

Employees28

Headquarters

Minneapolis, Minnesota

HeadquartersMinneapolis, Minnesota

Founded

2000

Founded2000

Employees

Employees28

DMAC Key Statistics

Market cap

176.57M

Market cap176.57M

Price-Earnings ratio

-6.93

Price-Earnings ratio-6.93

Dividend yield

—

Dividend yield—

Average volume

76.13K

Average volume76.13K

High today

$4.20

High today$4.20

Low today

$3.98

Low today$3.98

Open price

$3.98

Open price$3.98

Volume

89.30K

Volume89.30K

52 Week high

$6.82

52 Week high$6.82

52 Week low

$2.14

52 Week low$2.14

DiaMedica Therapeutics Inc. Common Stock

Why Robinhood?

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). Show more

DMAC Key Statistics

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).